Neurocrine Biosciences Inc NBIX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress
Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia
Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia
Trading Information
- Previous Close Price
- $164.63
- Day Range
- $162.99–169.89
- 52-Week Range
- $122.14–186.12
- Bid/Ask
- $145.00 / $174.85
- Shares Outstanding
- 101.22M
- Market Cap
- $17.09B
- Volume/Avg
- 2M / 1M
Key Statistics
- Price/Earnings (Normalized)
- 19.10
- Price/Sales
- 4.75
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.93%
Company Profile
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 2,500
- Website
- https://www.neurocrine.com
Competitors
Valuation
Metric | NBIX | TEVA | SNY |
|---|---|---|---|
Price/Earnings (Normalized) | 19.10 | 15.81 | 12.47 |
Price/Book Value | 4.41 | 6.28 | 1.39 |
Price/Sales | 4.75 | 2.94 | 1.96 |
Price/Cash Flow | 17.43 | 16.53 | 8.36 |
Price/Earnings
NBIX
TEVA
SNY
Financial Strength
Metric | NBIX | TEVA | SNY |
|---|---|---|---|
Quick Ratio | 1.72 | 0.51 | 0.21 |
Current Ratio | 2.04 | 0.95 | 1.12 |
Interest Coverage | — | 1.42 | 9.10 |
Quick Ratio
NBIX
TEVA
SNY
Profitability
Metric | NBIX | TEVA | SNY |
|---|---|---|---|
Return on Assets (Normalized) | 20.95% | 6.94% | 8.44% |
Return on Equity (Normalized) | 30.13% | 35.60% | 15.62% |
Return on Invested Capital (Normalized) | 25.23% | 13.90% | 12.02% |
Return on Assets
NBIX
TEVA
SNY
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|r?LD@Rj | LOCK|t$Wb> | $72B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|bM^##%?! | LOCK|L!&M& | $50B | |||
| Haleon PLC ADR HLN | LOCK|C^XRY^ | LOCK|L% | $39B | |||
| Zoetis Inc Class A ZTS | LOCK|&k^?HbF | LOCK|%> | $33B | |||
| Viatris Inc VTRS | LOCK|&jZzy@ | LOCK|&Xh | $23B | |||
| Elanco Animal Health Inc ELAN | LOCK|J$ | LOCK|Dx | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|lSZ#DV | LOCK|$wF | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|j$Y<Jq^ | LOCK|@G | $5B | |||
| Perrigo Co PLC PRGO | LOCK|^kZ^^f | LOCK|y# | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|PFV$<y | LOCK|NmKt | $2B |
United States